Psychiatry Advisor17h
FDA Approves TNKase for Acute Ischemic Stroke
The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.
Medscape1d
Single-Dose Intravenous Salbutamol Bolus for Managing Children With Acute Severe Asthma in the Emergency Department: Reanalysis of Data
Objective: To reanalyze data from two previous studies to provide stronger evidence of benefit for early use of single-dose intravenous bolus salbutamol in children with acute severe exacerbations ...
The Cardiology Advisor2d
TNKase Approved for Treatment of Acute Ischemic Stroke
The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.
Endovascular Today10d
Genentech’s TNKase Approved by FDA to Treat Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...
Healio10d
FDA approves TNKase for acute ischemic stroke in adults
The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...
Medscape28d
Single-Dose Intravenous Salbutamol Bolus for Managing Children With Acute Severe Asthma in the Emergency Department: Reanalysis of Data
[27] We consider the use of a single-dose intravenous salbutamol bolus in the ED to be more effective in achieving earlier clinical response in a subgroup of children with acute severe asthma.
Monthly Prescribing Reference10d
TNKase Approved for Treatment of Acute Ischemic Stroke
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...